BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 29146301)

  • 1. Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort.
    Hastie AT; Martinez FJ; Curtis JL; Doerschuk CM; Hansel NN; Christenson S; Putcha N; Ortega VE; Li X; Barr RG; Carretta EE; Couper DJ; Cooper CB; Hoffman EA; Kanner RE; Kleerup E; O'Neal WK; Paine R; Peters SP; Alexis NE; Woodruff PG; Han MK; Meyers DA; Bleecker ER;
    Lancet Respir Med; 2017 Dec; 5(12):956-967. PubMed ID: 29146301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study.
    Brightling CE; Bleecker ER; Panettieri RA; Bafadhel M; She D; Ward CK; Xu X; Birrell C; van der Merwe R
    Lancet Respir Med; 2014 Nov; 2(11):891-901. PubMed ID: 25208464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial.
    Pascoe S; Barnes N; Brusselle G; Compton C; Criner GJ; Dransfield MT; Halpin DMG; Han MK; Hartley B; Lange P; Lettis S; Lipson DA; Lomas DA; Martinez FJ; Papi A; Roche N; van der Valk RJP; Wise R; Singh D
    Lancet Respir Med; 2019 Sep; 7(9):745-756. PubMed ID: 31281061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Airway mucin MUC5AC and MUC5B concentrations and the initiation and progression of chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort.
    Radicioni G; Ceppe A; Ford AA; Alexis NE; Barr RG; Bleecker ER; Christenson SA; Cooper CB; Han MK; Hansel NN; Hastie AT; Hoffman EA; Kanner RE; Martinez FJ; Ozkan E; Paine R; Woodruff PG; O'Neal WK; Boucher RC; Kesimer M
    Lancet Respir Med; 2021 Nov; 9(11):1241-1254. PubMed ID: 34058148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials.
    Pascoe S; Locantore N; Dransfield MT; Barnes NC; Pavord ID
    Lancet Respir Med; 2015 Jun; 3(6):435-42. PubMed ID: 25878028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Standard technical specifications for methacholine chloride (Methacholine) bronchial challenge test (2023)].
    ; ;
    Zhonghua Jie He He Hu Xi Za Zhi; 2024 Feb; 47(2):101-119. PubMed ID: 38309959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort.
    Han MK; Quibrera PM; Carretta EE; Barr RG; Bleecker ER; Bowler RP; Cooper CB; Comellas A; Couper DJ; Curtis JL; Criner G; Dransfield MT; Hansel NN; Hoffman EA; Kanner RE; Krishnan JA; Martinez CH; Pirozzi CB; O'Neal WK; Rennard S; Tashkin DP; Wedzicha JA; Woodruff P; Paine R; Martinez FJ;
    Lancet Respir Med; 2017 Aug; 5(8):619-626. PubMed ID: 28668356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood eosinophils: a biomarker of COPD exacerbation reduction with inhaled corticosteroids.
    Siddiqui SH; Pavord ID; Barnes NC; Guasconi A; Lettis S; Pascoe S; Petruzzelli S
    Int J Chron Obstruct Pulmon Dis; 2018; 13():3669-3676. PubMed ID: 30464449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness using higher inhaled corticosteroid dosage in patients with COPD by different blood eosinophilic counts.
    Cheng SL; Lin CH
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2341-2348. PubMed ID: 27703344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peripheral blood eosinophils: a surrogate marker for airway eosinophilia in stable COPD.
    Negewo NA; McDonald VM; Baines KJ; Wark PA; Simpson JL; Jones PW; Gibson PG
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1495-504. PubMed ID: 27445469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies.
    Criner GJ; Celli BR; Singh D; Agusti A; Papi A; Jison M; Makulova N; Shih VH; Brooks L; Barker P; Martin UJ; Newbold P
    Lancet Respir Med; 2020 Feb; 8(2):158-170. PubMed ID: 31575508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial.
    Watz H; Tetzlaff K; Wouters EF; Kirsten A; Magnussen H; Rodriguez-Roisin R; Vogelmeier C; Fabbri LM; Chanez P; Dahl R; Disse B; Finnigan H; Calverley PM
    Lancet Respir Med; 2016 May; 4(5):390-8. PubMed ID: 27066739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical implications of blood eosinophil count in patients with non-asthma-COPD overlap syndrome COPD.
    Song JH; Lee CH; Kim JW; Lee WY; Jung JY; Park JH; Jung KS; Yoo KH; Park YB; Kim DK
    Int J Chron Obstruct Pulmon Dis; 2017; 12():2455-2464. PubMed ID: 28860740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study.
    McDowell PJ; Diver S; Yang F; Borg C; Busby J; Brown V; Shrimanker R; Cox C; Brightling CE; Chaudhuri R; Pavord ID; Heaney LG;
    Lancet Respir Med; 2021 Oct; 9(10):1174-1184. PubMed ID: 33971168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood eosinophil-guided oral prednisolone for COPD exacerbations in primary care in the UK (STARR2): a non-inferiority, multicentre, double-blind, placebo-controlled, randomised controlled trial.
    Ramakrishnan S; Jeffers H; Langford-Wiley B; Davies J; Thulborn SJ; Mahdi M; A'Court C; Binnian I; Bright S; Cartwright S; Glover V; Law A; Fox R; Jones A; Davies C; Copping D; Russell RE; Bafadhel M
    Lancet Respir Med; 2024 Jan; 12(1):67-77. PubMed ID: 37924830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exacerbation Frequency And Eosinophil Counts Among Patients With COPD Currently Prescribed Triple Therapy.
    Benson VS; Pascoe KC; Siddall J; Small M; Müllerová H
    Int J Chron Obstruct Pulmon Dis; 2019; 14():2711-2723. PubMed ID: 31819403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring COPD patients: systemic and bronchial eosinophilic inflammation in a 2-year follow-up.
    Pignatti P; Visca D; Zappa M; Zampogna E; Saderi L; Sotgiu G; Centis R; Migliori GB; Spanevello A
    BMC Pulm Med; 2024 May; 24(1):247. PubMed ID: 38764008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blood cell for the differentiation of airway inflammatory phenotypes in COPD exacerbations.
    Gao J; Chen B; Wu S; Wu F
    BMC Pulm Med; 2020 Feb; 20(1):50. PubMed ID: 32093672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis.
    Pavord ID; Lettis S; Anzueto A; Barnes N
    Lancet Respir Med; 2016 Sep; 4(9):731-741. PubMed ID: 27460163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-bronchodilator Reversibility of FEV
    Chou KT; Su KC; Hsiao YH; Huang SF; Ko HK; Tseng CM; Su VY; Perng DW
    Arch Bronconeumol; 2017 Oct; 53(10):547-553. PubMed ID: 28438346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.